Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Among predictors as defined by BMD change, both prior bisphosphonate treatment [odds ratio (95% confidence interval), 1.50 (1.01 to 2.24)] and vitamin D therapy [1.50 (1.01 to 2.22)] were significantly (P < 0.05) associated with teriparatide treatment failure.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A retrospective study of 494 patients was performed to assess the predictors of teriparatide therapy failure.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Predictors of teriparatide treatment failure in patients with low bone mass
Study design awaiting verification · Bone Reports · 2016
Original publication title
Predictors of teriparatide treatment failure in patients with low bone mass
© 2015 The Authors
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
While teriparatide is the only skeletal anabolic agent approved in the United States, treatment failure is a major concern which complicates its clinical utility. We sought to identify factors that predict response failure in patients with low bone mass.
Source: IntroductionAbstract: What methods does the paper describe?
We performed a retrospective study of adults with osteopenia or osteoporosis (T-scores < − 1.0 and − 2.5 SD below normal, respectively, at the total hip or lumbar spine) treated with teriparatide at the Mayo Clinic (Rochester, Minnesota) between November 2002: December 2012. Trained study investigators blinded to patient outcomes collected electronic medical record data. Potential response failure predictors were identified using univariate analysis. Multivariable logistic regression modeling was used to identify independent predictors of treatment failure based on either osteoporotic fragility fracture or BMD response.
Source: MethodAbstract: Results
During the 10-year period, 494 patients received teriparatide treatment and met eligibility criteria. Thirty-five patients had osteoporotic fractures, while 172 did not achieve a ≥ 3% BMD increase. Among predictors as defined by BMD change, both prior bisphosphonate treatment [odds ratio (95% confidence interval), 1.50 (1.01 to 2.24)] and vitamin D therapy [1.50 (1.01 to 2.22)] were significantly (P < 0.05) associated with teriparatide treatment failure. By contrast, no predictors were associated with treatment failure when fracture was the endpoint.
Source: ResultsAbstract: Conclusion
These data suggest that prior bisphosphonate or vitamin D exposure may predict response failure to teriparatide therapy. Although these findings may, in part, reflect increased severity or longer duration of disease, this knowledge should help guide clinicians and patients when therapy choices are made.
Source: ConclusionAuthors’ abstract
Introduction
While teriparatide is the only skeletal anabolic agent approved in the United States, treatment failure is a major concern which complicates its clinical utility. We sought to identify factors that predict response failure in patients with low bone mass.
Method
We performed a retrospective study of adults with osteopenia or osteoporosis (T-scores < − 1.0 and − 2.5 SD below normal, respectively, at the total hip or lumbar spine) treated with teriparatide at the Mayo Clinic (Rochester, Minnesota) between November 2002: December 2012. Trained study investigators blinded to patient outcomes collected electronic medical record data. Potential response failure predictors were identified using univariate analysis. Multivariable logistic regression modeling was used to identify independent predictors of treatment failure based on either osteoporotic fragility fracture or BMD response.
Results
During the 10-year period, 494 patients received teriparatide treatment and met eligibility criteria. Thirty-five patients had osteoporotic fractures, while 172 did not achieve a ≥ 3% BMD increase. Among predictors as defined by BMD change, both prior bisphosphonate treatment [odds ratio (95% confidence interval), 1.50 (1.01 to 2.24)] and vitamin D therapy [1.50 (1.01 to 2.22)] were significantly (P < 0.05) associated with teriparatide treatment failure. By contrast, no predictors were associated with treatment failure when fracture was the endpoint.
Conclusion
These data suggest that prior bisphosphonate or vitamin D exposure may predict response failure to teriparatide therapy. Although these findings may, in part, reflect increased severity or longer duration of disease, this knowledge should help guide clinicians and patients when therapy choices are made.
Highlights
- •
A retrospective study of 494 patients was performed to assess the predictors of teriparatide therapy failure.
- •
Prior treatment with bisphosphonate and vitamin D was found to be independent predictors.
- •
Future prospective studies are needed to evaluate other factors that are difficult to be assessed retrospectively.
Publication and source details
Original title: Predictors of teriparatide treatment failure in patients with low bone mass
Tarig Elraiyah; Adil H. Ahmed; Zhen Wang; Joshua N. Farr; Mohammad H. Murad; Matthew T. Drake
Bone Reports · 2016
⁎ Corresponding author at: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States.Department of Molecular Pharmacology and Experimental TherapeuticsMayo Clinic200 First Street SWRochesterMN55905United States Elraiyah.Tarig@mayo.edu© 2015 The Authors2015https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T08:30:51.352384+00:00
DOI: 10.1016/j.bonr.2015.11.001 · PMC4926837